US President Donald Trump’s push for most favored nation (MFN) pricing is set to boost the direct-to-patient (DTP) distribution model. However, experts warn that this approach comes with significant complexities.
According to William Lobb, vice-president of strategic initiatives at Indegene, the DTP model cannot independently reshape the broader healthcare system. “It’s not universally applicable,” he stated. This is due to various factors, including regulatory and logistical challenges.
Lobb’s comments come as companies begin to adopt the DTP model in response to changing market conditions. Despite its potential benefits, the model faces numerous hurdles that need to be addressed. As the industry navigates these complexities, it remains to be seen how the DTP distribution model will evolve in the coming months and years.
Source: https://insights.citeline.com/scrip/business/strategy/indegene-exec-on-dtp-distribution-as-a-tactical-solution-feasibility-of-mfn-model-CP4QA56M4VH6ZIDFPVJ22GCAS4